OTCMKTS:PRLX

Parallax Health Sciences Competitors

$0.02
0.00 (0.00 %)
(As of 04/9/2021 08:10 PM ET)
Add
Compare
Today's Range
$0.01
Now: $0.02
$0.02
50-Day Range
$0.01
MA: $0.01
$0.02
52-Week Range
$0.00
Now: $0.02
$0.07
Volume4,550 shs
Average Volume23,816 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Parallax Health Sciences (OTCMKTS:PRLX) Vs. OLK, OCDX, BDSX, LHDX, AKU, and NOTV

Should you be buying PRLX stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Parallax Health Sciences, including Olink Holding AB (publ) (OLK), Ortho Clinical Diagnostics (OCDX), Biodesix (BDSX), Lucira Health (LHDX), Akumin (AKU), and Inotiv (NOTV).

Parallax Health Sciences (OTCMKTS:PRLX) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Parallax Health Sciences and Olink Holding AB (publ), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Parallax Health Sciences0000N/A
Olink Holding AB (publ)0000N/A

Profitability

This table compares Parallax Health Sciences and Olink Holding AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Parallax Health SciencesN/AN/AN/A
Olink Holding AB (publ)N/AN/AN/A

Valuation & Earnings

This table compares Parallax Health Sciences and Olink Holding AB (publ)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Parallax Health SciencesN/AN/AN/AN/AN/A
Olink Holding AB (publ)N/AN/AN/AN/AN/A

Ortho Clinical Diagnostics (NASDAQ:OCDX) and Parallax Health Sciences (OTCMKTS:PRLX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Earnings & Valuation

This table compares Ortho Clinical Diagnostics and Parallax Health Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ortho Clinical DiagnosticsN/AN/AN/AN/AN/A
Parallax Health SciencesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Ortho Clinical Diagnostics and Parallax Health Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ortho Clinical Diagnostics011102.92
Parallax Health Sciences0000N/A

Ortho Clinical Diagnostics currently has a consensus target price of $24.2727, indicating a potential upside of 25.12%. Given Ortho Clinical Diagnostics' higher possible upside, equities research analysts plainly believe Ortho Clinical Diagnostics is more favorable than Parallax Health Sciences.

Profitability

This table compares Ortho Clinical Diagnostics and Parallax Health Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ortho Clinical DiagnosticsN/AN/AN/A
Parallax Health SciencesN/AN/AN/A

Summary

Ortho Clinical Diagnostics beats Parallax Health Sciences on 2 of the 2 factors compared between the two stocks.

Parallax Health Sciences (OTCMKTS:PRLX) and Biodesix (NASDAQ:BDSX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Valuation and Earnings

This table compares Parallax Health Sciences and Biodesix's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Parallax Health SciencesN/AN/AN/AN/AN/A
BiodesixN/AN/AN/AN/AN/A

Profitability

This table compares Parallax Health Sciences and Biodesix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Parallax Health SciencesN/AN/AN/A
BiodesixN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Parallax Health Sciences and Biodesix, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Parallax Health Sciences0000N/A
Biodesix00403.00

Biodesix has a consensus target price of $26.00, indicating a potential upside of 35.28%. Given Biodesix's higher possible upside, analysts plainly believe Biodesix is more favorable than Parallax Health Sciences.

Summary

Biodesix beats Parallax Health Sciences on 2 of the 2 factors compared between the two stocks.

Lucira Health (NASDAQ:LHDX) and Parallax Health Sciences (OTCMKTS:PRLX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Lucira Health and Parallax Health Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lucira Health01202.67
Parallax Health Sciences0000N/A

Lucira Health presently has a consensus target price of $22.00, suggesting a potential upside of 104.65%. Given Lucira Health's higher probable upside, research analysts clearly believe Lucira Health is more favorable than Parallax Health Sciences.

Earnings & Valuation

This table compares Lucira Health and Parallax Health Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lucira HealthN/AN/AN/AN/AN/A
Parallax Health SciencesN/AN/AN/AN/AN/A

Profitability

This table compares Lucira Health and Parallax Health Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lucira HealthN/AN/AN/A
Parallax Health SciencesN/AN/AN/A

Summary

Lucira Health beats Parallax Health Sciences on 2 of the 2 factors compared between the two stocks.

Akumin (NASDAQ:AKU) and Parallax Health Sciences (OTCMKTS:PRLX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Akumin and Parallax Health Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akumin00103.00
Parallax Health Sciences0000N/A

Institutional and Insider Ownership

30.4% of Akumin shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Akumin and Parallax Health Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkuminN/AN/AN/A
Parallax Health SciencesN/AN/AN/A

Earnings & Valuation

This table compares Akumin and Parallax Health Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkuminN/AN/AN/AN/AN/A
Parallax Health SciencesN/AN/AN/AN/AN/A

Summary

Akumin beats Parallax Health Sciences on 2 of the 2 factors compared between the two stocks.

Parallax Health Sciences (OTCMKTS:PRLX) and Inotiv (NASDAQ:NOTV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Profitability

This table compares Parallax Health Sciences and Inotiv's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Parallax Health SciencesN/AN/AN/A
InotivN/AN/AN/A

Valuation and Earnings

This table compares Parallax Health Sciences and Inotiv's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Parallax Health SciencesN/AN/AN/AN/AN/A
InotivN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and price targets for Parallax Health Sciences and Inotiv, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Parallax Health Sciences0000N/A
Inotiv0000N/A


Parallax Health Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
OLK
Olink Holding AB (publ)
0.0$37.11flat$4.47 billionN/A0.00
Ortho Clinical Diagnostics logo
OCDX
Ortho Clinical Diagnostics
1.8$18.91flat$4.32 billionN/A0.00
Biodesix logo
BDSX
Biodesix
1.6$19.22flat$503.65 millionN/A0.00
Lucira Health logo
LHDX
Lucira Health
1.6$10.71flat$331.02 millionN/A0.00News Coverage
Akumin logo
AKU
Akumin
0.6$3.10flat$228.09 millionN/A0.00
NOTV
Inotiv
0.0$20.20flat$221.51 millionN/A0.00
Relay Medical logo
RYMDF
Relay Medical
0.0$0.46flat$69.29 millionN/A0.00
Global WholeHealth Partners logo
GWHP
Global WholeHealth Partners
0.0$0.73flat$49.60 millionN/A0.00
Epigenomics logo
EPGNY
Epigenomics
0.6$13.77flat$0.00N/A0.00
ETAH
Eternity Healthcare
0.6$0.00flat$0.00N/A0.00Gap Up
MEDD
Medical Imaging
0.4$0.01flat$0.00N/A0.00Gap Down
Siemens Healthineers logo
SMMNY
Siemens Healthineers
0.5$28.08flat$0.00N/A0.00
WUXIF
WuXi AppTec
1.0$18.50flat$0.00N/A0.00News Coverage
Gap Down
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.